XEN 1101

Drug Profile

XEN 1101

Alternative Names: 1OP 2198; VRX 621698; XEN1101

Latest Information Update: 13 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unknown
  • Developer Xenon Pharmaceuticals
  • Class Antiepileptic drugs; Neuroprotectants; Small molecules
  • Mechanism of Action KCNQ potassium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Epilepsy

Most Recent Events

  • 07 Aug 2018 Xenon Pharmaceuticals completes enrolment in its phase I trial for Epilepsy (In volunteers) in United Kingdom (PO)
  • 07 Aug 2018 Xenon Pharmaceuticals completes enrolment in its phase Ib trial for Healthy volunteers in United Kingdom
  • 16 May 2018 Interim adverse events, efficacy and pharmacokinetics data from a phase I trial in Epilepsy released by Xenon Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top